| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|---|---|---|
| Q2 Adjusted Loss Per Share | Miss | $0.48 | $0.38 (3 Analysts) |
| Q2 Adjusted Net Loss | $10.20 mln | ||
| Q2 Net Loss | $13.15 mln | ||
| Q2 Income from Operations | -$13.10 mln |
US dermatology therapeutics firm's Q2 revenue declined yr/yr as prior-year included one-time milestone
Adjusted loss per share for Q2 missed analyst expectations
Company reported record demand for YCANTH and secured $27.5 mln credit facility to extend cash runway
YCANTH demand — Co said record demand for YCANTH drove higher product revenue, with dispensed applicator units up 28% sequentially and 46% yr/yr
Distribution partner deliveries — Co attributed increase in U.S. YCANTH product revenue primarily to increased deliveries to distribution partners
Higher operating expenses — Co said selling, general and administrative expenses rose due to increased commercial spend and sales force expansion, while R&D costs increased from Phase 3 program for common warts
